Faculty Opinions recommendation of KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS[G12C] inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature（2023）
关键词
inhibitor jdq443,phase iii trial,efficacy,c-mutated
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要